| 產(chǎn)品編號(hào) | bsk11002 |
| 英文名稱 | Human IL-2 ELISA Kit |
| 中文名稱 | 人白細(xì)胞介素2酶聯(lián)免疫試劑盒 |
| 別 名 | IL2, IL-2, TCGF, lymphokine, interleukin 2 |
 |
Specific References (2) | bsk11002 has been referenced in 2 publications.
[IF=17.521] Lizhen He. et al. Metabolic Reprogramming of NK Cells by Black Phosphorus Quantum Dots Potentiates Cancer Immunotherapy. Advanced Science. 2023 Jan;:2202519 ELISA ; Human.
[IF=10.273] Lai H et al. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling. Biomaterials. 2019 Jul 24;219:119377. ELISA ; Human.
|
| 種 屬 | Human |
| 線性范圍 | 7.81 - 500 pg/mL |
| 應(yīng)用范圍 | S/P/CC |
| 檢測(cè)限 | 4 pg/mL |
| 適用樣品基質(zhì) | cell culture supernates, serum, and plasma. |
| 保存條件 | Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles (Shipped with wet ice.). |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產(chǎn)品介紹 |
Interleukin 2 (IL-2) is a pleiotropic cytokine produced primarily by mitogen- or antigen-activated T lymphocytes. Human IL-2 (also known as T-cell growth factor) is produced by T-cells in response to antigenic or mitogenic stimulation. IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells promoting proliferation and maturation.IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendocytes. IL-2 is involved in treatment of cancers such as melanoma and renal cell cancer. It plays a key role in promoting the clonal expansion of antigen-specific T cells. In addition, IL-2 has also been shown to mediate multiple immune responses on a variety of cell types.
白介素-2(Interleukin-2,IL-2)是輔助型T淋巴細(xì)胞(TH)活化產(chǎn)生的細(xì)胞因子[1-2]。IL-2具有雙重調(diào)控免疫應(yīng)變的能力,可有效誘導(dǎo)細(xì)胞免疫和體液免疫應(yīng)答。 白介素（IL-2)的主要生理作用是刺激和維持T細(xì)胞的分化增殖。IL-2有關(guān)腫瘤的生物學(xué)活性包括：1.刺激自然殺傷(NK)細(xì)胞的增殖和活化，并增強(qiáng)其活性。2.誘導(dǎo)細(xì)胞毒性淋巴細(xì)胞，增強(qiáng)其溶細(xì)胞活性。3.誘導(dǎo)淋巴因子活化殺傷(LAK)細(xì)胞。LAK細(xì)胞具有廣譜的抗腫瘤活性，可以溶解多種腫瘤細(xì)胞。IL-2不僅是產(chǎn)生LAK細(xì)胞的必需淋巴因子，而且在它的存在下還能維持LAK細(xì)胞的增殖和長(zhǎng)期生長(zhǎng)，因此，在臨床抗腫瘤治療時(shí)往往把IL-2和LAK細(xì)胞同時(shí)給予，這就是惡性腫瘤的過繼免疫性治療(adoptiveimmunetherapy，AIT)。4.刺激腫瘤浸潤(rùn)淋巴細(xì)胞(TIL)的增生并增強(qiáng)其活性。動(dòng)物實(shí)驗(yàn)證明，TIL較LAK細(xì)胞的抗腫瘤活性高50～100倍。5.不僅能促進(jìn)T細(xì)胞增殖，且對(duì)細(xì)胞有促增殖和促分化作用。在腫瘤治療的動(dòng)物模型中已證明，當(dāng)T細(xì)胞中介抗瘤反應(yīng)強(qiáng)烈時(shí)，很低量的IL-2已足以激化抗瘤作用；但當(dāng)T細(xì)胞中介的抗瘤反應(yīng)很弱時(shí)，則需要很高劑量的IL-2。低劑量可以顯著地刺激T細(xì)胞，而激活NK及LAK細(xì)胞則要求很大劑量。因IL-2不能直接抗癌，用藥目的是最大限度地興奮免疫機(jī)制，以加強(qiáng)抗癌作用。以前常用的IL-2和LAK細(xì)胞聯(lián)合應(yīng)用治療惡性腫瘤，現(xiàn)已不再推薦，而代之以IL-2與腫瘤浸潤(rùn)淋巴細(xì)胞(TIL)聯(lián)合療法。6.rhIL-11為177個(gè)氨基酸組成的活性蛋白質(zhì)。其編碼基因位于19號(hào)染色體長(zhǎng)臂13區(qū)。作用于巨核細(xì)胞系較晚期階段的巨核細(xì)胞水平，促進(jìn)巨核細(xì)胞的增殖及成熟，并促進(jìn)血小板的產(chǎn)生。IL-11雖無巨核細(xì)胞集落刺激因子(Meg-CSF)的活性，但有巨核細(xì)胞增殖因子的活性，與GM-CSF及IL-3協(xié)同作用，可使CFU-MegDNA量增多。 |
